Changes in Adenosine Deaminase Activity in Patients with Type 2 Diabetes Mellitus and Effect of DPP-4 Inhibitor Treatment on ADA Activity.
10.4093/dmj.2011.35.2.149
- Author:
Jae Geun LEE
1
;
Dong Gu KANG
;
Jung Re YU
;
Young Ree KIM
;
Jin Soek KIM
;
Gwan Pyo KOH
;
Dae Ho LEE
Author Information
1. Department of Internal Medicine, Jeju National University Hospital, Jeju National University School of Medicine, Jeju, Korea. Ldhkso@jejunu.ac.kr
- Publication Type:Original Article
- Keywords:
Adenosine deaminase;
Diabetes mellitus, type 2;
Dipeptidyl peptidase
- MeSH:
Adenosine;
Adenosine Deaminase;
Alanine Transaminase;
Aspartate Aminotransferases;
Blood Glucose;
Diabetes Mellitus, Type 2;
Dipeptidyl Peptidase 4;
Fasting;
Glucose;
Humans;
Insulin;
Metformin;
Plasma;
T-Lymphocytes
- From:Diabetes & Metabolism Journal
2011;35(2):149-158
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Dipeptidyl peptidase 4 (DPP-4, also known as CD26) binds with adenosine deaminase (ADA) to activate T lymphocytes. Here, we investigated whether ADA activity is specifically affected by treatment with DPP-4 inhibitor (DPP4I) compared with other anti-diabetic agents. METHODS: Fasting ADA activity, in addition to various metabolic and biochemical parameters, were measured in 262 type 2 diabetes mellitus (T2DM) patients taking various anti-diabetic agents and in 46 non-diabetic control subjects. RESULTS: ADA activity was increased in T2DM patients compared with that in non-diabetic control subjects (mean+/-standard error, 23.1+/-0.6 U/L vs. 18.6+/-0.8 U/L; P<0.05). ADA activity was correlated with fasting plasma glucose (r=0.258, P<0.05), HbA1c (r=0.208, P<0.05), aspartate aminotransferase (r=0.325, P<0.05), and alanine aminotransferase (r=0.248, P<0.05). Compared with the well-controlled T2DM patients (HbA1c<7%), the poorly controlled group (HbA1c>9%) showed significantly increased ADA activity (21.1+/-0.8 U/L vs. 25.4+/-1.6 U/L; P<0.05). The effect of DPP4I on ADA activity in T2DM patients did not differ from those of other oral anti-diabetic agents or insulin. T2DM patients on metformin monotherapy showed a lower ADA activity (20.9+/-1.0 U/L vs. 28.1+/-2.8 U/L; P<0.05) compared with that of those on sulfonylurea monotherapy. CONCLUSION: Our results show that ADA activity is increased in T2DM patients compared to that in non-diabetic patients, is positively correlated with blood glucose level, and that DPP4I has no additional specific effect on ADA activity, except for a glycemic control- or HbA1c-dependent effect.
